Henry Schein’s (HSIC) “Outperform” Rating Reiterated at Robert W. Baird
Robert W. Baird reaffirmed their outperform rating on shares of Henry Schein Inc. (NASDAQ:HSIC) in a research note released on Tuesday. They currently have a $176.00 price target on the stock, up from their previous price target of $175.00.
Several other brokerages also recently weighed in on HSIC. Zacks Investment Research downgraded shares of Henry Schein from a hold rating to a sell rating in a report on Monday, August 8th. Bank of America Corp. initiated coverage on shares of Henry Schein in a report on Monday, September 12th. They issued a buy rating and a $185.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $157.92.
Shares of Henry Schein (NASDAQ:HSIC) traded down 0.49% during midday trading on Tuesday, reaching $162.32. 75,783 shares of the company traded hands. The firm has a market capitalization of $13.28 billion, a PE ratio of 27.50 and a beta of 1.05. Henry Schein has a 1-year low of $140.11 and a 1-year high of $183.00. The stock has a 50 day moving average price of $162.60 and a 200 day moving average price of $170.50.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.01. Henry Schein had a net margin of 4.42% and a return on equity of 17.84%. The company had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the company earned $1.46 EPS. Henry Schein’s quarterly revenue was up 9.3% on a year-over-year basis. Analysts expect that Henry Schein will post $6.57 earnings per share for the current fiscal year.
In other news, Director Paul Brons sold 3,381 shares of the stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $164.03, for a total transaction of $554,585.43. Following the transaction, the director now owns 13,715 shares in the company, valued at approximately $2,249,671.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.27% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in HSIC. Advisor Group Inc. acquired a new position in shares of Henry Schein during the second quarter worth about $106,000. Global X Management Co. LLC raised its position in shares of Henry Schein by 18.7% in the second quarter. Global X Management Co. LLC now owns 661 shares of the company’s stock worth $117,000 after buying an additional 104 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of Henry Schein by 0.4% in the second quarter. Quadrant Capital Group LLC now owns 742 shares of the company’s stock worth $128,000 after buying an additional 3 shares during the last quarter. Van ECK Associates Corp raised its position in shares of Henry Schein by 29.1% in the second quarter. Van ECK Associates Corp now owns 727 shares of the company’s stock worth $129,000 after buying an additional 164 shares during the last quarter. Finally, Mizuho Asset Management Co. Ltd. raised its position in shares of Henry Schein by 108.6% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 1,018 shares of the company’s stock worth $180,000 after buying an additional 530 shares during the last quarter. Hedge funds and other institutional investors own 91.98% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.